Inclusion Criteria:  Patient is male and aged > 18 years old History of localized adenocarcinoma of the prostate status post (s/p) radical prostatectomy An initial elevated PSA >= 0.2 followed by a subsequent confirmatory PSA >= 0.2 clinically suspicious for biochemically recurrent disease If the patients were previously taking androgen deprivation therapy (ADT), it should be discontinued at least 12 weeks prior to the study Patient willing to provide signed informed consent and willing to comply with all required study schedule events, where safe and feasible  Exclusion Criteria:  Patients with any medical condition or circumstance that the investigator believes may compromise the data collected or lead to a failure to fulfil the study requirements Patients who are planned to have an Iodinated contrast agent with computed tomography (CT) or gadolinium based contrast agent with MRI or other PET radiotracer < 24 hours prior to the PET scan Patients with contraindication to undergo MRI Patients with extreme claustrophobia Patients with prior allergy to MRI contrast agent